Navigation Links
Not Parkinson’s Disease Alon

Scientists claim that sequence variation in a gene linked to dopamine regulation, can lead not only to Parkinson’s disease but also to a craving for alcohol.//

The protein alpha synuclein (SNCA) plays an important role in the regulation of dopamine function. SNCA mutations can lead to significant problems, such as the neurodegenerative disorder Parkinson's disease, which is caused by a substantially reduced production of dopamine.

New findings show that sequence variation in the SNCA gene also contributes to whether or not an individual craves or does not crave alcohol.

Results are published in the April issue of Alcoholism: Clinical & Experimental Research.

"Several years ago," explained Tatiana M. Foroud, director of the division of Alcoholism: Clinical & Experimental Research, "animal researchers identified a gene called SNCA, which appeared to contribute to the alcohol-drinking patterns of specially bred rats. Further studies have shown that different levels of SNCA exist in the brains of rodents that prefer alcohol versus those who do not like alcohol."

Since then, added corresponding-author Foroud, human research has suggested that SNCA might be important in determining an individual's craving for alcohol. "Using previous research as a building base," she said, "we utilized a large sample, a different type of analysis technique, and genotyped more sequence variants in the gene to provide a more comprehensive survey of the role of this gene in the craving for alcohol and alcoholism."

Foroud and her colleagues examined a sample of 219 alcoholic families of European American descent. Thirty single nucleotide polymorphisms (SNPs) were genotyped across the SNCA gene, and two phenotypes – alcohol dependence and alcohol craving – were also analyzed.

Although findings indicate no association between any of the SNCA SNPs and alcohol dependence, eight SNPs did have an association with alcohol c raving.

"This strongly suggests that sequence variation in SNCA contributes to whether an individual craves or does not crave alcohol," said Foroud. "Interestingly, we found that this association cannot be expanded to everyone who has alcohol dependence. Rather, it seems to be limited to that subset of alcoholics who also indicate that they crave alcohol when they do not have the ability to obtain it."

"The strongest evidence for association was observed in a region encompassing one particular end of the gene," said Alison Goate, professor of psychiatry, genetics and neurology, at Washington University. "This is interesting because it appears to confirm a previous association between SNPs in the same region of the rat SNCA gene that differ between alcohol-preferring and non-preferring rats. It is this subgroup of alcoholics who have cravings that seem to be influenced by variation in the SNCA gene."

Foroud said that this study supports the emerging belief in the alcohol-research field that there are "subtypes" of alcoholics, in this case, a subset of individuals in whom variation in SNCA is an important contributor to the risk of developing alcoholism.

"Understanding the role of SNCA in sensitivity to craving may enable the future development of drugs to help alleviate the symptoms of craving," added Goate, "improving the chances that an individual might be able to stop drinking."

"Alcoholism is a complex disorder and we are identifying pieces of the puzzle that help us to understand why some individuals develop alcohol dependence and others do not," said Foroud. "The role of SNCA is only one of these pieces."


Related medicine news :

1. NPIL withdraws Parkinson’s dru
2. Parkinson’s Drug Linked to Gamblin
3. Delaying Parkinson’s Diseas
4. New Drug For Parkinson’s Disease With Less Side Effect
5. Embryonic Cells Might Prevent Parkinson’s Disease From Worsenin
6. Magnetic Stimulation For Parkinson’s Diseas
7. Exercising regularly can reduce the risk of Parkinson’s diseas
8. Fetal Cell Transplant Found To Improve Movement In Patients With Parkinson’s Disease
9. New Medicine For Parkinson’s disease
10. A New Addition Could Help Patients With Parkinson’s Disease
11. Milk intake increases the risk of Parkinson’s disease in midlife
Post Your Comments:

(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: